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Abstract
Background: End-stage kidney disease (ESKD) is a significant public health concern disproportionately affecting
African Americans (AAs). Type 2 diabetes (T2D) is the leading cause of ESKD in the USA, and efforts to uncover
genetic susceptibility to diabetic kidney disease (DKD) have had limited success. A prior genome-wide association
study (GWAS) in AAs with T2D-ESKD was expanded with additional AA cases and controls and genotypes imputed
to the higher density 1000 Genomes reference panel. The discovery analysis included 3432 T2D-ESKD cases and
6977 non-diabetic non-nephropathy controls (N = 10,409), followed by a discrimination analysis in 2756 T2D non-
nephropathy controls to exclude T2D-associated variants.
Results: Six independent variants located in or near RND3/RBM43, SLITRK3, ENPP7, GNG7, and APOL1 achieved
genome-wide significant association (P < 5 × 10−8) with T2D-ESKD. Following extension analyses in 1910 non-
diabetic ESKD cases and 908 non-diabetic non-nephropathy controls, a meta-analysis of 5342 AA all-cause ESKD
cases and 6977 AA non-diabetic non-nephropathy controls revealed an additional novel all-cause ESKD locus at
EFNB2 (rs77113398; P = 9.84 × 10–9; OR = 1.94). Exclusion of APOL1 renal-risk genotype carriers identified two
additional genome-wide significant T2D-ESKD-associated loci at GRAMD3 and MGAT4C. A second variant at GNG7
(rs373971520; P = 2.17 × 10–8, OR = 1.46) remained associated with all-cause ESKD in the APOL1-negative analysis.
Conclusions: Findings provide further evidence for genetic factors associated with advanced kidney disease in AAs
with T2D.
Keywords: African Americans, Genome-wide association study, Type 2 diabetes, Diabetic kidney disease, End-stage
kidney disease
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Introduction
Increasing evidence suggests that genetic factors play a
major role in susceptibility to end-stage kidney disease
(ESKD). This is particularly relevant in African Americans
(AAs) where incidence rates of ESKD are more than three-
fold greater than European Americans (EAs) [1]. The mor-
tality rates for ESKD, dialysis, and transplant patients are
136, 166, and 30 per 1000 patient-years, respectively, and
account for 7.2% of Medicare-paid claims costs [1]. Dia-
betes, of which 95% of patients have type 2 diabetes (T2D),
remains the leading reported cause of ESKD in the USA ac-
counting for > 44% of cases [1]. Improvements in glycemic,
lipid, and blood pressure control have not markedly re-
duced the prevalence of diabetic kidney disease (DKD) [1,
2]. In addition, familial aggregation of DKD is independent
from socioeconomic status and established environmental
risk factors [3, 4]. Although the G1 and G2 alleles in the
apolipoprotein L1 gene (APOL1) contribute to 50–70% of
non-diabetic ESKD in AAs, they do not fully explain the
excess risk of T2D-attributed ESKD (T2D-ESKD) in this
population [5–7].
Genome-wide association studies (GWAS) have identi-
fied > 70 genome-wide significant variants associated with
chronic kidney disease (CKD), albuminuria, or renal func-
tion in European ancestry populations [8–11]. However,
few loci were associated with DKD in diverse populations
and they do not consistently replicate, in part due to limited
sample sizes [12–18]. The etiology of kidney complications
in patients with T2D is likely more heterogeneous than in
patients with type 1 diabetes [16]. Therefore, careful pheno-
typing and larger sample sizes are required to improve
statistical power. To explore the genetic architecture of
advanced kidney disease in T2D, we extended our previous
GWAS (2890 ESKD patients and 1719 non-diabetic non-
nephropathy controls) efforts in a larger sample of AAs
with severe kidney disease. Association analyses were per-
formed in six independent AA cohorts (Wake Forest
School of Medicine, WFSM; Family Investigation of
Nephropathy and Diabetes, FIND; Atherosclerosis Risk in
Communities Study, ARIC; Multi-Ethnic Study of Athero-
sclerosis, MESA; Jackson Heart Study, JHS; and Coronary
Artery Risk Development in Young Adults, CARDIA) for
T2D-ESKD or non-diabetic ESKD through a multi-stage
study design (Fig. 1). This encompassed 15,075 AAs classi-
fied into four phenotypic groups: T2D-ESKD cases (N =
3432), non-diabetic non-nephropathy controls (N = 6977),
T2D-lacking nephropathy controls (N = 2756), and non-
diabetic ESKD cases (N = 1910).
In the discovery stage, GWAS was performed in 3432
T2D-ESKD cases and 6977 non-diabetic non-nephropathy
controls, followed by a discrimination analysis to exclude
T2D-associated loci in 2756 T2D non-nephropathy con-
trols. Extension analyses were performed in 1910 AAs
with non-diabetic ESKD and 908 non-nephropathy con-
trols to assess the contribution of T2D-ESKD-associated
loci to non-diabetic kidney disease. A meta-analysis of dia-
betic and non-diabetic ESKD cases assessed genetic asso-
ciations in all-cause ESKD. APOL1-associated forms of
Fig. 1 Workflow of T2D-ESKD GWAS in AAs (baseline model)
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non-diabetic kidney disease and T2D often co-exist in pa-
tients. As such, many diabetic patients with kidney disease
may be misclassified as having DKD, since diagnostic kid-
ney biopsies are usually not performed. Herein, a second
GWAS analysis excluding individuals with APOL1
renal-risk genotypes was performed to minimize mis-
classification of T2D-ESKD.
Results
Study overview
This study has > 80% power to detect common variants
(MAF ≥ 0.10) with moderate effect (OR ≥ 1.3) at a signifi-
cance level of 5 × 10−8 (http://csg.sph.umich.edu/abecasis/
cats/). In all, seven genome-wide significant loci (P < 5 ×
10−8) associated with T2D-ESKD were identified in either
the baseline model (RND3/RBM43, SLITRK3, ENPP7,
GNG7, and APOL1) or APOL1-negative model (ENPP7,
GRAMD3, andMGAT4C). In addition to APOL1, two loci,
EFNB2 and GNG7, also reached genome-wide significance
in the all-cause ESKD meta-analysis under either the base-
line or APOL1-negative models.
Clinical characteristics of study participants
Tables 1 and 2 include detailed characteristics of study par-
ticipants. ESKD cases were recruited from the WFSM
(Affy6.0, Axiom, and MEGA), FIND, and ARIC studies. In-
dividuals with T2D-ESKD or T2D-lacking nephropathy
were older (or of similar age) compared to the non-diabetic
non-nephropathy controls at recruitment. However, the
average age at diagnosis of T2D in T2D-ESKD cases and
T2D-lacking nephropathy controls were younger than non-
diabetic non-nephropathy controls at recruitment. All T2D
non-nephropathy controls and non-diabetic, non-nephrop-
athy controls had normal eGFR ≥ 60ml/min/1.73m2. In
addition, non-diabetic non-nephropathy controls had fast-
ing glucose levels < 126mg/dl. Controls with T2D-lacking
nephropathy were more obese than T2D-ESKD or non-dia-
betic ESKD cases and non-diabetic, non-nephropathy con-
trols, except that T2D-ESKD cases in ARIC were more
obese than the other groups.
Stage 1 and stage 2 T2D-ESKD association analysis
In stage 1 discovery, GWAS was conducted separately in
three datasets: (1) 1513 T2D-ESKD cases and 5299 non-
diabetic non-nephropathy controls genotyped on Affy6.0,
contributed by WFSM, FIND, ARIC, JHS, MESA, and
CARDIA (stage 1a); (2) 1700 T2D-ESKD cases and 770
non-diabetic non-nephropathy controls from WFSM geno-
typed with Axiom Biobank genotyping array (stage 1b); and
(3) 219 T2D-ESKD cases and 908 non-diabetic, non-ne-
phropathy controls from WFSM genotyped on MEGA
(stage 1c). A meta-analysis (stage 2) was performed to com-
bine association results for 3432 T2D-ESKD cases and
6977 non-diabetic, non-nephropathy controls from stages
1a, 1b, and 1c. An inflation factor λ of 1.013 was observed
after correcting for genomic control (Additional file 1:
Figure S1), suggesting that population structure and cryptic
relatedness were sufficiently adjusted. Among variants
demonstrating suggestive associations (P < 1 × 10−5), 59 var-
iants with I2 ≥ 80% were excluded due to high heterogen-
eity in effect sizes across studies. A total of 478 remaining
variants were assessed in a discrimination analysis (81 of
them achieved genome-wide significance; Additional file 1:
Table S2).
Stage 3 discrimination analysis
To determine whether the T2D-ESKD associations identi-
fied in stage 1 meta-analysis were driven by association
with T2D per se, a discrimination analysis was performed
for T2D contrasting 2756 AAs with T2D-lacking nephrop-
athy with 6977 non-diabetic non-nephropathy controls
from stage 1 (Affy6.0, Axiom, MEGA; Additional file 1:
Table S3). We subsequently excluded 174 of 478 T2D-ESK-
D-associated variants nominally associated with T2D in the
absence of nephropathy. Among the remaining T2D-ESKD
associations, top variants representing 6 independent asso-
ciations achieved genome-wide significance (Table 3,
Fig. 2a). The strongest association was observed for
rs9622363 located at APOL1 (P = 1.42 × 10−10, OR = 0.77,
EAF = 0.45). This variant was in moderate linkage disequi-
librium (r2 = 0.33 and 0.34, respectively in YRI) with the
APOL1 G1 alleles (rs60910145, rs73885319) associated
with non-diabetic ESKD [6]. The second strongest associ-
ation was at rs58627064, an intergenic variant located near
SLITRK3, (P = 6.81 × 10−10, OR = 1.62, EAF = 0.06). Two
independent signals, rs142563193 (P = 1.24 × 10−8, OR =
0.74, EAF = 0.23) and rs142671759 (P = 5.53 × 10−9, OR =
2.26, EAF = 0.02) on chromosome 17 located near ENPP7,
respectively, were also genome-wide significant. In
addition, two associations with T2D-ESKD, rs4807299 (P =
3.21 × 10−8, OR = 1.67, EAF = 0.05) located in GNG7 and
rs72858591 (P = 4.54 × 10−8, OR = 1.43, EAF = 0.10) located
in RND3/RBM43 were identified (Fig. 1a).
Stage 4 non-diabetic ESKD analysis and stage 5 all-cause
ESKD meta-analysis
After the discrimination stage, 304 variants exhibiting sug-
gestive association with T2D-ESKD (P < 1 × 10−5) were
tested in 1910 independent non-diabetic ESKD cases and
908 controls from stage 1c. The goal of the stage 4 analysis
was to evaluate the contribution of T2D-ESKD-associated
loci to non-diabetic kidney disease. After excluding variants
with heterogeneity I2 ≥ 80%, 25 variants were nominally
associated with non-diabetic ESKD (P < 0.05). Strong asso-
ciations (1.27 × 10−29 < P < 8.86 × 10−15) were observed in
the APOL1-MYH9 region, confirming their role in non-dia-
betic kidney disease. An all-cause ESKD meta-analysis, in-
cluding 5342 all-cause ESKD and 6977 non-diabetic
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non-nephropathy controls, was conducted to evaluate the
generalizability of the 25 T2D-ESKD-associated variants
with broader forms of ESKD (stage 5). Thirty-five
genome-wide significant variants at two loci were found to
be associated with all-cause ESKD, including 15 variants
within or near EFNB2 and 20 variants at APOL1 (Fig. 1b).
The top association in APOL1 was rs9622363 (P = 1.96 ×
10−25, OR = 0.68, EAF = 0.43), and the top signal near
EFNB2 was rs77113398 (P = 9.84 × 10−9, OR = 1.94, EAF =
0.023) (Table 4, Fig. 2b). Four additional independent loci
demonstrated suggestive association (P < 5 × 10−6) with
all-cause ESKD at LPP, FSTL5, OPRK1/ATPV1H, and
SYBU/KCNV1 (Table 4, Fig. 2b).
Association analysis excluding APOL1 renal-risk-genotype
carriers
A secondary analysis was performed excluding APOL1
renal-risk-genotype carriers in T2D-ESKD cases and
non-diabetic non-nephropathy controls (APOL1-nega-
tive model) to enrich for T2D-associated ESKD. The
baseline model showed a strong association of APOL1
and MYH9 with T2D-ESKD (Table 3, Fig. 1a) suggesting
that some cases may have been misclassified and more
likely had non-diabetic ESKD. A total of 664 T2D-ESKD
cases and 918 non-diabetic non-nephropathy controls
were excluded from stage 1 analysis, leaving 2768
T2D-ESKD cases and 6059 controls in the APOL1-nega-
tive model. Nominal associations with T2D-ESKD (P <
1 × 10−5) were observed with 522 variants (66 of them
achieved genome-wide significance; Additional file 1:
Table S2), and these were selected for stage 3 discrimin-
ation analysis. Two hundred twenty-three variants that
had evidence of association with T2D per se (Add-
itional file 1: Table S4) and 24 variants showing strong
heterogeneity (I2 ≥ 80) in the meta-analysis were re-
moved. Among the genome-wide significant variants
identified in the baseline model, rs142671759 in ENPP7
(P = 4.10 × 10−8, OR = 2.30, EAF = 0.024) showed a con-
sistent association with T2D-ESKD in the APOL1-nega-
tive model. Two additional variants reached
genome-wide significance, rs75029938 in GRAMD3 (P =
2.02 × 10–9, OR = 1.89, EAF = 0.042) and rs17577888 in
the MGAT4C region (P = 3.87 × 10−8, OR = 0.67, EAF =
0.087) (Table 5, Fig. 3a).
We further tested 275 suggestive T2D-ESKD associations
that passed discrimination and had I2 < 80 in 1019 add-
itional AA non-diabetic ESKD cases that excluded APOL1
renal-risk-genotype carriers. Fifteen variants showed nom-
inal evidence of association with non-diabetic ESKD. These
were subsequently tested in an all-cause ESKD
meta-analysis including 3787 all-cause ESKD cases and
6059 non-diabetic non-nephropathy controls of which
APOL1 renal-risk-genotype carriers were excluded. A
2-base pair deletion in GNG7, rs373971520 (P = 2.17 ×
10−8, OR = 1.46, EAF = 0.11), achieved genome-wide signifi-
cant association with all-cause ESKD (Fig. 3b). Seven add-
itional loci displayed nominal association with all-cause
ESKD (P < 5 × 10−6), including LPP, ALK/YPEL5,
MNX1-AS1/UBE3C, NUP98, LINC01075/LINC00448,
TMCO5A, and SULF2/LINC01522 (Table 6). The top asso-
ciations from the baseline model had moderate attenuation
in significance, despite the similar effect sizes, due in part
to the reduced sample size (Additional file 1: Table S5).
In addition, a third GWAS was performed with
APOL1 included as a covariate in the model (APO-
L1-adjusted model) and comparing −log (P) values
with baseline and APOL1-negative models. High
correlation (Person correlation coefficient r = 0.95)
was observed between APOL1-adjusted and APOL1--
negative models. The results of all three comparisons
are included in the supplementary documentation
(Additional file 1: Figure S2).
Table 2 Clinical characteristics of participants genotyped using Axiom and MEGA arrays (stage 1b and 1c)
WFSM-Axiom WFSM-MEGA
T2D-
ESKD
Non-diabetic
non-nephropathy
T2D-lacking
nephropathy
T2D-
ESKD
Non-diabetic
non-nephropathy
T2D-lacking
nephropathy
Non-diabetic
ESKD
N 1700 770 663 219 908 201 1910
Females (%) 56 49 64 49 59 62 41
Age (years) 62.0 ± 10.8 47.9 ± 12.0 55.7 ± 11.6 62.0 ± 11.0 44.8 ± 13.9 55.8 ± 9.5 55.4 ± 14.4
Age of onset of diabetes (years) 39.7 ± 12.8 – 46.2 ± 12.3 37.8 ± 9.6 – 43.7 ± 10.3 –
Duration of diabetes prior to ESKD
(years)
19.1 ± 10.0 – – 20.4 ± 9.5 – – –
Duration of ESKD (years) 3.6 ± 3.6 – – 4.1 ± 3.1 – – 6.2 ± 5.8
Fasting serum glucose (mg/dl) 184 ± 89 96 ± 22 163 ± 92 127 ± 33 96 ± 11 174 ± 62 90 ± 3
eGFR (ml/min/1.73m2) – 96.0 ± 20.8 91.3 ± 19.7 – 85.9 ± 17.3 95.2 ± 17.3 –
Body mass index (kg/m2) 30.7 ± 7.1 29.6 ± 7.4 33.1 ± 7.8 30.8 ± 7.0 29.7 ± 6.6 33.0 ± 6.5 27.8 ± 7.2
Categorical data expressed as percentage; continuous data as mean ± SD
Abbreviations: T2D type 2 diabetes, ESKD end-stage kidney disease, N number, eGFR estimated glomerular filtration rate
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Discussion
We report the results of a high-density GWAS investi-
gating genetic susceptibility to T2D-ESKD in 15,075
AAs. Top variants associated with T2D-ESKD were sub-
sequently assessed for association with non-diabetic
ESKD, and a meta-analysis was performed to test for
their generalizability to common forms of ESKD. Eight
independent associations in seven genetic loci displayed
genome-wide significant association with T2D-ESKD in
the baseline or APOL1-negative models, including RND
3/RBM43, SLITRK3, ENPP7, GNG7, APOL1, GRAMD3,
and MGAT4C. In addition to APOL1, two genome-wide
significant loci were associated with all-cause ESKD,
EFNB2 and GNG7. Further, 10 genetic loci demon-
strated nominal association with all-cause ESKD (P <
5 × 10−6), including LPP, FSTL5, OPRK1/ATP6V1H,
Fig. 2 Locus plots of genome-wide associations in the baseline model. a Locus plots of T2D-ESKD associations at P < 5 × 10−8 in the baseline
model. b Locus plots of all-cause ESKD-associated variants at P < 5 × 10− 8 in the baseline model. Abbreviations: T2D, type 2 diabetes; ESKD, end-
stage kidney disease; Baseline model: adjusted for age, sex, and PC1. APOL1 risk genotype carriers were included; reference genome: hg19/1000
Genomes Nov 2014 AFR.
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SYBU/KCNV1, ALK/YPEL5, MNX1-AS1/UBE3C, NUP
98, LINC01075/LINC00448, TMCO5A, and SULF2/LIN
C01522.
The most significant association with T2D-ESKD (OR=
0.77, P= 1.42 × 10−10) and all-cause ESKD (OR= 0.69, P=
1.96 × 10−25) in the baseline model was an intronic variant
rs9622363 in the APOL1 region associated with non-diabetic
kidney disease in individuals with African ancestry. Condi-
tioning on the APOL1 G1 and G2 alleles dramatically dimin-
ishes its significance [6]. rs9622363 is reported to alter
transcription factor (TF) binding motifs (Additional file 1:
Table S6). In a recent study, rs9622363 and APOL1 G1 al-
leles formed a haplotype that achieved the strongest associ-
ation with CKD in Nigerians [19]. Unlike G1 or G2, the
major allele in rs9622363 (G, EAF = 0.57) is associated with
the risk of CKD. After excluding APOL1 renal-risk-genotype
carriers, association with rs9622363 was attenuated. This
confirmed that rs9622363 and APOL1 G1 and G2 alleles
contribute to the same signal. Identification of rs9622363 in
the baseline model may suggest misclassification of some
cases as T2D-ESKD.
An intergenic variant (rs72858591) located between a
GTPase protein gene RND3 and RBM43, encoding RNA
binding motif protein 43, revealed genome-wide significant
association with T2D-ESKD. It is associated with TF bind-
ing motif changes and overlap with both promoter and en-
hancer regions (Additional file 1: Table S6). An
independent intergenic variant (rs7560163, r2 = 0.01, YRI)
in this region was previously associated with T2D in AAs
[20]. In contrast, rs72858591 was not associated with T2D
(P = 0.073) in the present study. This may suggest that two
different sets of variations in this locus independently
contribute to T2D and T2D-ESKD, a possible pleiotropic
effect. Two independent variants (rs142563193 and
rs142671759) that were genome-wide significantly associ-
ated with T2D-ESKD are located near ENPP7. These vari-
ants overlap with enhancer and promoter regions, DNase
hypersensitive peaks, and/or TF binding motifs (Add-
itional file 1: Table S6). The protein encoded by ENPP7 is
an intestinal alkaline sphingomyelin phosphodiesterase that
converts sphingomyelin to ceramide and phosphocholine.
ENPP7 reportedly affects cholesterol absorption [21], and
numerous studies suggest that high-density lipoprotein
cholesterol levels are risk factors for CKD in patients with
diabetes [22–24].
Two variants located in GNG7 were associated with
either T2D-ESKD (rs4807299; P = 3.21 × 10−8, baseline
model) or all-cause ESKD (rs373971520; P = 2.17 × 10−8;
APOL1-negative model). Rs4807299 is associated with TF
binding motif changes and overlaps with both promoter
and enhancer regions (Additional file 1: Table S6). GNG7
encodes G Protein Subunit Gamma 7, involved in central
nervous system function [25] and cancer risk [26, 27].
Since African Americans with diabetes and proteinuria
often do not get a diagnostic kidney biopsy, their ESKD
is typically presumed to have been caused by DKD.
However, APOL1-associated non-diabetic kidney disease
may be the true cause of kidney disease in many such
patients. Analyses excluding APOL1 renal-risk-genotype
carriers created a more homogeneous case group and
provided an opportunity to uncover the genetic architec-
ture of T2D-ESKD that is independent of APOL1 effect.
In the APOL1-negative model, in addition to replicating
ENPP7 identified in the baseline model, two novel loci
Table 4 All-cause ESKD-associated variants at P < 5 × 10–6 in baseline model
Lead variant CHR POS Locus Effect/other
alleles
Info Stage 2 (3432
T2D-ESKD cases
vs. 6977 non-diabetic
non-nephropathy
controls)
Stage 4 (1910 non-
diabetic ESKD cases
vs. 908 non-diabetic
non-nephropathy
controls)
Stage 5: Meta-analysis (5342
all-cause ESKD cases vs. 6977
non-diabetic non-nephropathy
controls)
EAF OR (95%
CI)
P EAF OR (95%
CI)
P EAF OR (95%
CI)
P HetP
rs76971802 3 188607071 LPP T/C 0.95 0.087 1.35
(1.19,1.54)
8.66E
−06
0.084 1.42
(1.08,1.87)
0.013 0.087 1.35
(1.2,1.52)
1.36E
−06
0.86
rs5863506 4 162909217 FSTL5 TA/T 0.96 0.33 1.22
(1.12,1.32)
1.64E
−06
0.33 1.19
(1.01,1.40)
0.033 0.33 1.21
(1.12,1.30)
4.57E
−07
0.87
rs141746998 8 54310938 OPRK1/
ATP6V1H
CAT/C 0.94 0.031 0.62
(0.5,0.76)
9.40E
−06
0.034 0.61
(0.39,0.93)
0.022 0.031 0.61
(0.5,0.75)
1.44E
−06
0.96
rs11997465 8 110891977 SYBU/
KCNV1
C/G 0.99 0.28 1.22
(1.12,1.33)
3.21E
−06
0.28 1.21
(1.02,1.43)
0.026 0.28 1.22
(1.13,1.31)
6.72E
−07
0.65
rs77113398 13 107103906 EFNB2 A/G 0.93 0.023 1.94
(1.52,2.47)
1.25E
−07
0.021 1.87
(1.08,3.24)
0.025 0.023 1.94
(1.55,2.43)
9.84E
−09
0.96
rs9622363 22 36656555 APOL1 A/G 0.95 0.45 0.77
(0.72,0.84)
1.42E
−10
0.35 0.42
(0.36,0.48)
4.32E−29 0.43 0.68
(0.64,0.73)
1.96E
−25
1.14E
−09
Baseline model: adjusted for age, sex, and PC1; APOL1 risk genotype carriers were included
Abbreviations: T2D type 2 diabetes, ESKD end-stage kidney disease, CHR chromosome, POS position, EAF effect allele frequency, OR odds ratio, CI confidence
interval, P, P value, Info average imputation quality, HetP heterogeneity P value
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achieved genome-wide significant association with T2D-
ESKD: GRAMD3 (rs75029938; P = 2.02 × 10−9) and MGA
T4C (rs17577888; P = 3.87 × 10−8). Functional annotation
suggested that both variants are co-located with TF binding
motifs. Rs75029938 may fall into enhancer and promoter
regions, and rs17577888 was associated with transcript
abundance of FLVCR1 gene in peripheral blood monocytes
(P = 6.41 × 10−6; Additional file 1: Table S6). Genetic vari-
ation in GRAMD3 has been associated with adiposity in a
multi-ethnic genome-wide meta-analysis [28]. Previous
studies suggest that obesity is a major risk factor for DKD
[29]. MGAT4C encodes Mannosyl (Alpha-1,3-)-Glycopro-
tein Beta-1,4-N-Acetylglucosaminyltransferase, Isozyme C,
which participates in the transfer of N-acetylglucosamine
Fig. 3 Locus plots of genome-wide associations in the APOL1-negative model. a Locus plots of T2D-ESKD associations at P< 5 × 10−8 in the APOL1-
negative model. b Locus plots of all-cause ESKD associations at P< 5 × 10−8 in the APOL1-negative model. Abbreviations: T2D, type 2 diabetes; ESKD, end-
stage kidney disease; P, P value; APOL1-negative mode, adjusted for age, sex, and PC1. APOL1 risk genotype carriers excluded; reference genome: hg19/
1000 Genomes Nov 2014 AFR.
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(GlcNAc) to the core mannose residues of N-linked
glycans. The potential involvement of MGAT4C in DKD
requires further study.
This analysis included a cohort of AAs with non-diabetic
ESKD to evaluate the generalizability of T2D-ESKD-associ-
ated loci in common forms of CKD. The meta-analysis
combining cases with T2D-ESKD and non-diabetic ESKD
identified two novel genome-wide significant loci
associated with all-cause ESKD in addition to APOL1;
rs77113398 near EFNB2 (P = 9.84 × 10−9; baseline model)
and rs373971520 in GNG7 (2.17 × 10−8; APOL1-negative
model). Rs77113398 overlaps with enhancer, promoter re-
gions, and DNase peaks (Additional file 1: Table S6). Prior
genome scans in AAs identified significant evidence for
linkage to ESKD on chromosome 13q33 including the
EFNB2 region in both diabetic ESKD and non-diabetic
ESKD [30, 31]. A follow-up study examined 28 tagging
variants spanning 39 kilobases (kb) of the EFNB2 coding
region demonstrated nominal associations between two
variants and all-cause ESKD [32]. However, these reported
variants were not correlated with rs77113398. Ephrin-B2
(EFNB2) is expressed in the developing nephron; interac-
tions between ephrin-B2 and its receptors play an import-
ant role in glomerular microvascular assembly [33]. In
addition, ephrin-B2 reverse signaling protects against peri-
tubular capillary rarefaction by regulating angiogenesis and
vascular stability during kidney injury [34]. Ephrin-B1 also
co-localizes with CD2-associated protein (CD2AP) and
nephrin at the podocyte slit diaphragm and plays an
important role in maintaining barrier function at the slit
diaphragm [35]. Ephrin B4 receptor kinase transgenic mice
develop glomerulopathy, manifested by fused afferent and
efferent arterioles bypassing the glomeruli [36]. Thus, mul-
tiple lines of evidence support the potential EFNB2 associ-
ation with CKD, and it is the most promising causal gene
underlying association of rs77113398.
This study has strengths and limitations. Although the
multi-stage study design was well-powered including
15,075 AAs, it lacked replication of T2D-ESKD associa-
tions, particularly for rare variants. Furthermore, several
genome-wide significant signals showed significantly
different effect sizes across stages, which was likely
attributable to sample size differences across stages, and a
consequence of the “winner’s curse,” a phenomenon de-
scribing that the true genetic effect size is overestimated
because of the initial positive finding. Future replication is
needed to confirm these findings. There are few other
existing collections with appropriate samples in AAs; this
limited replication efforts. Moreover, it is difficult to
exclude all individuals misclassified with DKD due to the
frequent lack of kidney biopsies. Therefore, we carefully
excluded samples with ESKD attributed to non-diabetic
etiologies based on clinical phenotypes and subsequently
excluded APOL1 renal-risk-genotype carriers at high risk
Table 6 All-cause ESKD-associated variants at P < 5 × 10−6 in APOL1-negative model
Lead variant CHR POS Locus Effect/other
allele
*Info Stage 2: Meta-analysis
(2768 T2D-ESKD cases
vs. 6059 non-diabetic
non-nephropathy
controls)
Stage 4 (1019
non-diabetic ESKD
cases vs. 733
non-diabetic
non-nephropathy
controls)
Stage 5 (3787 all-cause ESKD
cases vs. 6059 non-diabetic
non-nephropathy controls)
EAF OR (95%
CI)
P EAF OR(95%
CI)
P EAF OR (95%
CI)
P HetP
rs12472637 2 30304514 ALK/YPEL5 A/G 0.94 0.33 0.81 (0.74,
0.89)
6.05E
−06
0.36 0.8 (0.66,
0.96)
0.019 0.33 0.82 (0.76,
0.89)
4.47E
−06
0.83
rs76971802 3 188607071 LPP T/C 0.95 0.09 1.43 (1.24,
1.65)
1.06E
−06
0.08 1.45 (1.03,
2.05)
0.032 0.088 1.42 (1.24,
1.62)
5.76E
−07
0.93
rs6459733 7 156930550 MNX1-AS1/
UBE3C
G/C 0.97 0.39 1.25 (1.15,
0.87)
1.32E
−07
0.39 1.25 (1.03,
1.53)
0.026 0.39 1.24 (1.15,
1.35)
7.17E
−08
0.83
rs4910809 11 3813850 NUP98 C/G 0.98 0.02 0.53 (0.4,
0.7)
9.46E
−06
0.02 0.53 (0.29,
0.95)
0.034 0.023 0.53 (0.41,
0.69)
2.12E
−06
0.63
rs219020 13 63013622 LINC01075/
LINC00448
C/T 0.97 0.14 1.31 (1.17,
0.86)
6.84E
−06
0.11 1.38 (1.02,
1.87)
0.037 0.14 1.31 (1.17,
1.47)
2.12E
−06
0.58
rs113452507 15 37954309 TMCO5A C/G 0.92 0.16 1.29 (1.15,
1.45)
9.71E
−06
0.16 1.38 (1.07,
1.77)
0.014 0.16 1.31 (1.18,
1.45)
8.48E
−07
0.93
rs373971520 19 2568805 GNG7 –/CA 0.81 0.11 1.47 (1.28,
1.7)
8.97E
−08
0.11 1.39 (1.01,
1.91)
0.044 0.11 1.46 (1.28,
1.67)
2.17E
−08
0.016
rs6094913 20 46561443 SULF2/
LINC01522
G/A 0.93 0.09 0.72 (0.63,
1.6)
8.28E
−06
0.10 0.67 (0.48,
0.91)
0.012 0.092 0.72 (0.63,
0.83)
2.5E
−06
0.70
Abbreviations: T2D type 2 diabetes, ESKD end-stage kidney disease, CHR chromosome, POS position, EAF effect allele frequency, OR odds ratio, CI confidence
interval, P P value, *Info imputation quality, HetP heterogeneity P value;
APOL1-negative model: adjusted for age, sex, and PC1; APOL1 risk genotype carriers were excluded
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for non-diabetic ESKD. This should minimize
misclassification.
Conclusion
In conclusion, a GWAS was conducted in AAs with
T2D-ESKD and seven genetic loci displayed genome-
wide significant evidence of association, including in
RND3/RBM43, SLITRK3, ENPP7, GNG7, APOL1,
GRAMD3, and MGAT4C. Beyond APOL1, EFNB2 and
GNG7 were also associated with non-diabetic ESKD and
revealed genome-wide significant association with
all-cause ESKD. Future investigations including genetic
replication and experimental validation of these newly
identified associations are required to assess their poten-
tial impacts on the biological processes leading to ad-
vanced DKD in populations with recent African
ancestry.
Methods
Study participants
Study participants were recruited by the Wake Forest
School of Medicine (WFSM; N = 8052), Family Investiga-
tion of Nephropathy and Diabetes (FIND; N = 926), Jack-
son Heart Study (JHS; N = 1912), Atherosclerosis Risk in
Communities Study (ARIC; N = 2221), Coronary Artery
Risk Development in Young Adults (CARDIA; N = 912),
and Multi-Ethnic Study of Atherosclerosis (MESA; N =
1052). Analyses were approved by local institutional re-
view boards, and all participants provided written in-
formed consent. Cases were considered to have
T2D-ESKD, including severe DKD, when diabetes was
diagnosed ≥ 5 years prior to the onset of ESKD or with
diabetic retinopathy to ensure adequate T2D duration,
with renal replacement therapy, estimated glomerular fil-
tration rate (eGFR) ≤ 30 ml/min/1.73 m2 (CKD4), or
urine albumin to creatinine ratio (UACR) ≥ 300 mg/g
(macroalbuminuria). Participants with CKD4 or macro-
albuminuria (N = 138) were included as cases given their
high risk of developing ESKD. T2D was diagnosed
according to American Diabetes Association criteria
with a fasting blood glucose ≥ 126mg/dl, 2-h oral glu-
cose tolerance test glucose ≥ 200 mg/dl, random glucose
≥ 200 mg/dl, use of diabetes medications, or physician-
diagnosed diabetes. Cases with non-diabetic ESKD lacked
diabetes (or had T2D for < 5 years) at the initiation of
renal replacement therapy, and ESKD was attributed to
chronic glomerular disease (e.g., focal segmental glomeru-
losclerosis), HIV-associated nephropathy, hypertension, or
unknown cause. Patients with ESKD attributed to surgical
or urologic causes, polycystic kidney disease, autoimmune
disease, hepatitis, IgA nephropathy, membranous glomer-
ulonephritis, membranoproliferative glomerulonephritis,
or monogenic kidney diseases were excluded. Non-
diabetic non-nephropathy controls included participants
without diabetes or kidney disease (eGFR ≥ 60ml/min/
1.73m2 and UACR < 30mg/g). Subjects with T2D-lacking
nephropathy had eGFR ≥ 60ml/min/1.73m2 and UACR
< 30mg/g.
Sample preparation, genotyping, imputation, and quality
control
The study participants were genome-wide genotyped
using three different platforms: (1) 8704 samples re-
cruited from WFSM, ARIC, CARDIA, JHS, MESA, and
FIND were genotyped on the Affymetrix Genome-wide
Human single nucleotide polymorphism (SNP) array 6.0
(Affy6.0); (2) 3133 samples recruited from WFSM were
genotyped on the Affymetrix Axiom Biobank Genotyp-
ing Array (Axiom); and (3) 3238 samples recruited from
WFSM were genotyped on the Illumina Multi-Ethnic
Genotyping Array (MEGA). Quality control and imput-
ation were performed separately by each genotyping
platform as described below.
Variants that passed quality control (QC) were imputed
to a combined haplotype reference panel including the
1000 Genomes phase 3 cosmopolitan reference panel (Oc-
tober 2014 version) [37] and a version of the African Gen-
ome Variation Project (AGVP) reference panel including
640 African ancestry haplotypes kindly provided by the
African Partnership for Chronic Disease Research and
Wellcome Trust Sanger Institute [38]. Pre-phasing was
performed using SHAPEIT2 [39], and imputation was
performed using IMPUTE2 [40]. Post-imputation QC was
conducted to exclude variants with allele mismatch or
with large frequency discrepancy (≥ 0.2) with the reference
panel (0.2 × frequency in EUR + 0.8 × frequency in AFR)
and imputation info score < 0.4. A subset of samples was
directly genotyped for APOL1 G1 and G2 variants using
Sequenom (Sequenom, San Diego, CA). The concordance
was 95% with imputed genotypes.
Affy6.0 datasets
As described previously [41], 1513 T2D-ESKD cases, 5299
non-diabetic non-nephropathy controls, and 1892 T2D
non-nephropathy controls from WFSM, FIND, JHS, ARIC,
CARDIA, and MESA cohorts were genotyped using Affy6.0
(Table 1). In each study, standard QC measures were ap-
plied to exclude variants with call rate < 95%, minor allele
frequency (MAF) < 0.01, or showing departure from
Hardy-Weinberg Equilibrium (HWE) (P < 0.0001). Sample
QC was performed to exclude subjects with call rates <
95%, DNA contamination, duplicates, or population out-
liers. Given that CARDIA, JHS, and MESA lacked cases
with T2D-ESKD, samples from these studies were com-
bined for imputation and association analyses along with
WFSM, FIND, and ARIC.
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Axiom dataset
At WFSM, 1700 AA cases with T2D-ESKD, 770 AA
controls without diabetes or nephropathy, and 663 AA
controls with T2D who lacked nephropathy were geno-
typed on a customized Axiom genotyping array (Table 2).
Detailed variant information, custom content design, in-
cluding fine mapping of candidate regions, genotyping
methods, and QC were previously reported [42]. In brief,
this array included approximately 264K coding variants
and insertions/deletions (indels), 70K loss-of-function
variants, 2K pharmacogenomic variants, 23K eQTL
markers, 246K multi-ethnic population-based
genome-wide tag markers, and 115K custom content
markers. Variants with call rates < 95%, departure from
HWE (P < 0.0001), and monomorphic variants were ex-
cluded. A total of 724,530 variants were successfully
called for downstream QC, imputation, and analyses.
Sample QC was performed to exclude individuals with
low call rate (< 95%), gender discordance, DNA
contamination, duplication, or population outliers.
MEGA dataset
At WFSM, 1910 non-diabetic ESKD cases, 219 T2D-
ESKD cases, 201 controls with T2D lacking nephropa-
thy, and 908 non-diabetic non-nephropathy controls
were genotyped on the MEGA array (Table 2). This
array was designed to improve fine-mapping and func-
tional discovery by increasing variant coverage across
multiple ethnicities. The array includes (1) backbone
content containing highly informative variants for
GWAS and exome analyses in ancestrally diverse popu-
lations and (2) custom content used to replicate or
generalize index GWAS associations, augment GWAS
tagging variants in priority regions, enhance exome
content in priority regions, fine-map GWAS loci, iden-
tify functional regulatory variants, explore medically
important variants, and identify novel variant loci in
candidate pathways [43]. Genotyping was performed at
WFSM. DNA from cases and controls were equally in-
terleaved on 96-well plates to minimize artifactual er-
rors during sample processing. A total of 48 samples
sequenced as part of the 1000 Genomes Project [44] at
the Coriell Institute for Medical Research were in-
cluded in genotyping and had a concordance rate of
98.57%. Genotype calling was performed using Geno-
meStudio (Illumina, CA, USA). Variants with missing
position, missing allele, allele mismatch, call rates <
95%, departure from HWE (P < 0.0001), frequency dif-
ference > 0.2 comparing with 1000 Genome Project
phase 3 reference panel, and monomorphic variants
were removed. Multiple probe sets were compared, and
only the one with the highest call rate was kept. A total
of 1,705,970 variants were successfully called for
downstream QC, imputation, and analyses. Sample QC
was performed to exclude individuals with low call rate
(< 95%), gender discordance, DNA contamination, du-
plication, or population outliers. DNA swapping was
identified and corrected.
Statistical analysis
Discovery stage
We used a multi-stage study design to identify variants
associated with T2D-ESKD and their potential role in
all-cause ESKD. In the discovery stage, 3432 T2D-ESKD
cases and 6977 non-diabetic non-nephropathy controls
from all three datasets were included (Fig. 1). Associ-
ation analysis was performed for each dataset using a lo-
gistic mixed model method implemented in the program
GMMAT [45] under an additive genetic model. This
method controls for population structure and cryptic
relatedness through including a genetic relationship
matrix (GRM) estimated from a set of high-quality auto-
somal variants as a random effect. The principal compo-
nent analysis was performed using EIGENSOFT [46] for
each genotyping platform. The first eigenvector (PC1)
along with age and sex was used as covariates. A
meta-analysis was performed in the three datasets using
a fixed effect inverse variance weighting method imple-
mented in METAL [47]. Suggestive associations for
T2D-ESKD with P < 1 × 10−5, minor allele count (MAC)
> 400, and heterogeneity I2 < 80 were selected for dis-
crimination analysis.
Discrimination stage
To determine whether putative T2D-ESKD-associated loci
in the discovery stage were driven by associations with
T2D per se, a meta-analysis combining 2756 AAs with
T2D-lacking nephropathy and 6977 non-diabetic non-ne-
phropathy controls from the three datasets (Affy6.0,
Axiom, and MEGA) was performed (stage 3, Fig. 1). Vari-
ants showing nominal association (P < 0.05) with T2D
were excluded to remove T2D-associated variants.
Extension analysis of non-diabetic ESKD and meta-analysis
of all-cause ESKD
Genetic variants showing suggestive association with T2D-
ESKD (P < 1 × 10−5) but not associated with T2D were ex-
amined in a non-diabetic ESKD cohort including 1910
non-diabetic ESKD cases and 908 non-diabetic non-ne-
phropathy controls from the WFSM-MEGA dataset for as-
sociation with non-diabetic etiologies of kidney disease
(stage 4). Variants showing nominal association (P < 0.05)
were tested in a meta-analysis of all-cause ESKD using all
T2D-ESKD, non-diabetic ESKD, and controls from the three
datasets (N= 12,319, Affy6.0, Axiom, MEGA) (Fig. 1). This
meta-analysis evaluated whether T2D-ESKD associations
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contributed to the risk of all-cause ESKD. We also looked
up our top kidney disease-associated variants for putative as-
sociation with T2D in AAs from the MEDIA consortium
(N= 15,043 cases and 22,318 controls); SNPs with P < 0.05
after multiple comparison corrections were removed.
Exclusion of APOL1 risk genotype carriers
The APOL1 G1 and G2 alleles contribute to risk for
non-diabetic kidney disease [6, 48]. To minimize mis-
classification of T2D-ESKD, a second analysis was per-
formed excluding APOL1 two-renal-risk-variant carriers
and those with missing APOL1 genotypes from T2D-
ESKD cases and non-diabetic non-nephropathy controls
(APOL1-negative model). This analysis reduced the het-
erogeneity of the population despite reducing sample
size and having lower statistical power. Specifically, 308
T2D-ESKD cases and 630 controls from the Affy6.0
datasets, 323 T2D-ESKD cases, and 113 controls from
the Axiom dataset, and 33 T2D-ESKD cases and 175
controls from the MEGA dataset were removed. In
addition, we removed 891 of 1910 all-cause ESKD cases.
This analysis may unmask the effects of other non-dia-
betic ESKD loci beyond APOL1. Individuals were con-
sidered APOL1 renal-risk-variant carriers if they carried
two G1 alleles (rs60910145 G allele, rs73885319 G al-
lele), two G2 alleles (rs143830837, 6 base pair in-frame
deletion), or were compound heterozygotes (one G1 and
one G2 allele) [6].
Functional characterization
Proxies of genome-wide significant T2D-ESKD-associated
variants (r2 ≥ 0.7 in 1000 Genomes AFR population) from
the baseline and APOL1-negative models were selected
using LDlink [49]. The lead variants and proxies were then
queried for functional annotations from HaploReg [50],
which included chromatin state and protein binding anno-
tation from the Roadmap Epigenomics [51] and ENCODE
projects [52], sequence conservation across mammals, the
effect of variants on regulatory motifs, and gene expression
from eQTL studies.
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